Small molecules used in screening
| 17-AAG | CHIR258 | JAK1i | Nilotinib | SB-43152 |
| 8 Azaguanine | CHIR265 | JAK3i | P38i | SB203580 |
| ABT-864 | CI-1033 | JNK2i | Pan-JAKi | Sorafenib |
| Adiphenine | CP-690550 | JNKIIi | PD153035 | SRCi |
| AG490 | CYC-202 | KN92 | PD325901 | Staurosporine |
| AKTIV | Dasatinib | KN93 | PD98059 | STO609 |
| AKTX | EGFRi | Lapatinib | PI-103 | Sunitinib |
| AMPK | Erlotinib | LSD1 | Piperine | SYKi |
| Anisomycin | Estradiol | LY294002 | PKC412 | Thapsigargin |
| AZD-1152 | Gefitinib | LY333531 | PP2 | Trichostatin A |
| Azithromycin | Go6976 | MEK1/2 | Proguanil | Tunicamycin |
| BAY-11 | GW-786034 | Menadione | PTK787 | Vorinostat |
| BIRB-796 | H-89 | MLN-8054 | R1881 | VX-680 |
| Boldine | Harmane | MLN518 | Resveratrol | Zardaverine |
| cAMP | Imatinib | QNZ | SB-202190 | ZD-6474 |
| 17-AAG | CHIR258 | JAK1i | Nilotinib | SB-43152 |
| 8 Azaguanine | CHIR265 | JAK3i | P38i | SB203580 |
| ABT-864 | CI-1033 | JNK2i | Pan-JAKi | Sorafenib |
| Adiphenine | CP-690550 | JNKIIi | PD153035 | SRCi |
| AG490 | CYC-202 | KN92 | PD325901 | Staurosporine |
| AKTIV | Dasatinib | KN93 | PD98059 | STO609 |
| AKTX | EGFRi | Lapatinib | PI-103 | Sunitinib |
| AMPK | Erlotinib | LSD1 | Piperine | SYKi |
| Anisomycin | Estradiol | LY294002 | PKC412 | Thapsigargin |
| AZD-1152 | Gefitinib | LY333531 | PP2 | Trichostatin A |
| Azithromycin | Go6976 | MEK1/2 | Proguanil | Tunicamycin |
| BAY-11 | GW-786034 | Menadione | PTK787 | Vorinostat |
| BIRB-796 | H-89 | MLN-8054 | R1881 | VX-680 |
| Boldine | Harmane | MLN518 | Resveratrol | Zardaverine |
| cAMP | Imatinib | QNZ | SB-202190 | ZD-6474 |
For each molecule, at least 3 doses were tested. Cell viability was quantified using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay.